혈소판 시장 : 기회, 성장 요인, 업계 동향 분석 및 예측(2025-2034년)

The Global Blood Platelets Market was valued at USD 5.9 billion in 2024 and is estimated to grow at a CAGR of 3.9% to reach USD 8.8 billion by 2034.

The expansion of the market is driven by the increasing demand for blood transfusions, rising awareness of blood donation and platelet transfusion, and the growing prevalence of chronic and hematological disorders. Additionally, the rising number of surgical procedures and emergency hospitalizations further fuels the demand. Innovations in platelet processing and storage, development of artificial and lyophilized platelets, and strategic collaborations between biotech companies are key growth factors. Platelets play a critical role in clotting and preventing excessive bleeding, making them essential for trauma care, surgery, and patients undergoing chemotherapy or other intensive treatments. Government initiatives, hospital networks, and global blood organizations are supporting the adoption of platelet transfusions worldwide.

The apheresis-derived platelets segment held a 53.1% share in 2024. Platelets are collected directly from individual donors using automated apheresis systems that separate platelets while returning other blood components. This method produces higher platelet volumes per donation and minimizes risks associated with alloimmunization and transfusion-related infections. Apheresis platelets are especially critical for patients requiring multiple transfusions, such as those undergoing cancer therapy or bone marrow transplants.

The hemato-oncology segment was valued at USD 1.5 billion in 2024. This segment covers blood cancer treatments, including leukemia, lymphoma, and myeloma, where platelet transfusions are vital to manage chemotherapy-induced thrombocytopenia. Patients undergoing intensive cancer treatments frequently require repeated platelet transfusions to reduce the risk of bleeding complications.

North America Blood Platelets Market held a significant 26.8% share in 2024. The region's advanced healthcare infrastructure, robust awareness of blood donation, and strong demand for transfusions in cancer care, trauma treatment, and complex surgical procedures drive the market. Adoption of automated apheresis systems and pathogen reduction technologies ensures safety and operational efficiency. Extensive platelet donation networks supported by government initiatives enhance the availability of blood platelets.

Prominent companies operating in the Global Blood Platelets Market include America's Blood Centers, American Association of Blood Banks (AABB), American National Red Cross, Blood Centers of America, Brazilian Red Cross, Canada Blood Services, French Red Cross, German Red Cross, Indian Red Cross Society, Italian Red Cross, Japanese Red Cross Society, OneBlood, Red Cross Society of China, South African Red Cross, Spanish Red Cross, the European Blood Alliance (EBA), and the Italian National Blood Centre. Companies in the Blood Platelets Market are strengthening their position through multiple strategies. They focus on technological innovation, including automated apheresis systems and pathogen reduction methods, to improve safety, efficiency, and product quality. Strategic partnerships with hospitals, healthcare providers, and local blood donation networks expand geographic reach and improve donor accessibility. Firms invest in R&D to develop artificial and lyophilized platelets that enhance shelf life and reduce dependency on donors.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Platelet type trends
  • 2.2.3 Application trends
  • 2.2.4 End Use trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of chronic and blood-related disorders
    • 3.2.1.2 Growing demand for blood transfusions
    • 3.2.1.3 Rise in awareness regarding blood donations and platelets transfusions
    • 3.2.1.4 Rising number of surgical procedures
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High risk of transmissions of infections
    • 3.2.2.2 High cost of the treatment
  • 3.2.3 Opportunities
    • 3.2.3.1 Expansion of platelet-rich plasma (PRP) applications in regenerative medicine
    • 3.2.3.2 Technological advancements in automated platelet production
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 LAMEA
• 3.5 Technology and innovation landscape
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Reimbursement scenario
• 3.7 Pricing analysis, by region, 2021-2034
  • 3.7.1 North America
    • 3.7.1.1 U.S.
    • 3.7.1.2 Canada
  • 3.7.2 Europe
    • 3.7.2.1 Germany
    • 3.7.2.2 UK
    • 3.7.2.3 France
    • 3.7.2.4 Spain
    • 3.7.2.5 Italy
  • 3.7.3 Asia Pacific
    • 3.7.3.1 China
    • 3.7.3.2 Japan
    • 3.7.3.3 India
    • 3.7.3.4 Australia
    • 3.7.3.5 South Korea
  • 3.7.4 Latin America
    • 3.7.4.1 Brazil
    • 3.7.4.2 Mexico
    • 3.7.4.3 Argentina
  • 3.7.5 MEA
    • 3.7.5.1 South Africa
    • 3.7.5.2 Saudi Arabia
    • 3.7.5.3 UAE
• 3.8 Challenges in supply chain and logistics
• 3.9 Impact of awareness campaigns on donation rates
• 3.10 Future market trends
• 3.11 Gap analysis
• 3.12 Porter's analysis
• 3.13 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
  • 4.3.1 Global
  • 4.3.2 North America
  • 4.3.3 Europe
  • 4.3.4 Asia Pacific
  • 4.3.5 LAMEA
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers & acquisitions
  • 4.6.2 Partnerships & collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Platelet Type, 2021 - 2034 ($ Mn & Units)

• 5.1 Key trends
• 5.2 Whole-blood derived platelet
• 5.3 Apheresis derived platelets

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Hemophilia
• 6.3 Thrombocytopenia
• 6.4 Perioperative indications
• 6.5 Platelet function disorders
• 6.6 Hemato-oncology
• 6.7 Other applications

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Ambulatory surgical centers
• 7.4 Other End Use

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn & Units)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 MEA
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 American Association of Blood Banks (AABB)
• 9.2 American National Red Cross
• 9.3 America's Blood Centers
• 9.4 Blood Centers of America
• 9.5 Brazilian Red Cross
• 9.6 Canada Blood Services
• 9.7 French Red Cross
• 9.8 German Red Cross
• 9.9 Indian Red Cross Society
• 9.10 Italian Red Cross
• 9.11 Japanese Red Cross Society
• 9.12 OneBlood
• 9.13 Red Cross Society of China
• 9.14 South African Red Cross
• 9.15 Spanish Red Cross
• 9.16 The European Blood Alliance (EBA)
• 9.17 The Italian National Blood Centre